Search

• GSK, Fondazione Telethon and Ospedale San Raffaele announce EU regulatory submission for gene therapy to treat rare disease ADA-SCID

  Media

  Today announced the submission of a marketing application to the EMA for a gene therapy (GSK2696273) to treat patients with a rare disease

  https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/

  First published: 05 May 2015

• GSK announces start of phase III study of sirukumab in Giant Cell Arteritis

  Media

  GSK announced that dosing has commenced in a phase III study evaluating sirukumab.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis/

  First published: 25 November 2015

• Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD

  Media

  GSK & THRX announced that CHMP of EMA has issued a positive opinion recommending marketing authorisation for UMEC/VI ,brand name Anoro®

  https://www.gsk.com/en-gb/media/press-releases/anoro-umeclidinium-vilanterol-receives-positive-opinion-from-the-chmp-in-europe-for-the-treatment-of-copd/

  First published: 20 February 2014

• GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing in Japan

  Media

  GSK and THRX today announced the start of a Phase III efficacy and study of a combination treatment of the inhaled corticosteroid (ICS).

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-phase-iii-study-of-fluticasone-furoatevilanterol-in-copd-commenced-to-support-potential-future-filing-in-japan/

  First published: 22 April 2014

• Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® Study to Understand Mortality and MorbidITy (SUMMIT) in COPD

  Media

  GSK & THRX announced that recruitment of patients into the study known as SUMMIT, has completed enrolment.

  https://www.gsk.com/en-gb/media/press-releases/patient-recruitment-completes-in-landmark-relvar-breo-ellipta-study-to-understand-mortality-and-morbidity-summit-in-copd/

  First published: 13 March 2014

• Ebola vaccine trials fast-tracked by international consortium

  Media

  Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine

  https://www.gsk.com/en-gb/media/press-releases/ebola-vaccine-trials-fast-tracked-by-international-consortium/

  First published: 28 August 2014

• GSK announces first-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study

  Media

  GSK announced, phase IIIb/IV study to investigate combination therapy of ambrisentan and tadalafil in treatment naïve patients...

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-line-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study/

  First published: 08 September 2014

• New England Journal of Medicine publishes positive results from COMBI-v study of trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination

  Media

  Results published in NEJM show that treatment with trametinib (Mekinist™) & Tafinlar™ improved OS compared to vemurafenib monotherapy

  https://www.gsk.com/en-gb/media/press-releases/new-england-journal-of-medicine-publishes-positive-results-from-combi-v-study-of-trametinib-mekinist-and-dabrafenib-tafinlar-combination/

  First published: 16 November 2014

• The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial

  Media

  In line with IDMC unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed.

  https://www.gsk.com/en-gb/media/press-releases/the-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-does-not-meet-first-co-primary-endpoint-in-phase-iii-melanoma-clinical-trial/

  First published: 05 September 2013

• Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

  Media

  ViiV announced that the CHMP of EMA has issued a positive opinion recommending marketing authorisation for Tivicay® (dolutegravir).

  https://www.gsk.com/en-gb/media/press-releases/tivicay-dolutegravir-receives-positive-chmp-opinion-in-europe-for-the-treatment-of-hiv/

  First published: 22 November 2013